Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
Total Valuation
Orchestra BioMed Holdings has a market cap or net worth of $253.98M. The enterprise value is $251.73M.
Market Cap$253.98M
Enterprise Value$251.73M
Share Statistics
Orchestra BioMed Holdings has 58,520,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,520,900
Owned by Insiders29.69%
Owned by Institutions27.30%
Financial Efficiency
Orchestra BioMed Holdings’s return on equity (ROE) is -0.84 and return on invested capital (ROIC) is -52.40%.
Return on Equity (ROE)-0.84
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.40%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee478.31K
Profits Per Employee-752.87K
Employee Count70
Asset Turnover0.29
Inventory Turnover0.61
Valuation Ratios
The current PE Ratio of Orchestra BioMed Holdings is ―. Orchestra BioMed Holdings’s PEG ratio is 90.81.
PE Ratio―
PS Ratio4758.67
PB Ratio2.51K
Price to Fair Value2.51K
Price to FCF-3.22K
Price to Operating Cash Flow-3.40
PEG Ratio90.81
Income Statement
In the last 12 months, Orchestra BioMed Holdings had revenue of 33.48M and earned -52.95M in profits. Earnings per share was -1.11.
Revenue33.48M
Gross Profit33.29M
Operating Income-51.81M
Pretax Income-52.95M
Net Income-52.95M
EBITDA-51.48M
Earnings Per Share (EPS)-1.11
Cash Flow
In the last 12 months, operating cash flow was -48.96M and capital expenditures -489.00K, giving a free cash flow of -49.45M billion.
Operating Cash Flow-48.96M
Free Cash Flow-49.45M
Free Cash Flow per Share-0.85
Dividends & Yields
Orchestra BioMed Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.94
52-Week Price Change23.30%
50-Day Moving Average4.22
200-Day Moving Average3.65
Relative Strength Index (RSI)48.65
Average Volume (3m)233.58K
Important Dates
Orchestra BioMed Holdings upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Orchestra BioMed Holdings as a current ratio of 6.45, with Debt / Equity ratio of 51.18%
Current Ratio6.45
Quick Ratio6.43
Debt to Market Cap<0.01
Net Debt to EBITDA0.64
Interest Coverage Ratio-45.13
Taxes
In the past 12 months, Orchestra BioMed Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Orchestra BioMed Holdings EV to EBITDA ratio is -3.09K, with an EV/FCF ratio of -3.22K.
EV to Sales4.76K
EV to EBITDA-3.09K
EV to Free Cash Flow-3.22K
EV to Operating Cash Flow-3.25K
Balance Sheet
Orchestra BioMed Holdings has $106.51M in cash and marketable securities with $32.44M in debt, giving a net cash position of $74.08M billion.
Cash & Marketable Securities$106.51M
Total Debt$32.44M
Net Cash$74.08M
Net Cash Per Share$1.27
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 99.43%, with operating margin of -154.73%, and net profit margin of -158.16%.
Gross Margin99.43%
Operating Margin-154.73%
Pretax Margin-158.16%
Net Profit Margin-158.16%
EBITDA Margin-153.75%
EBIT Margin-154.73%
Analyst Forecast
The average price target for Orchestra BioMed Holdings is $13.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.40
Price Target Upside208.76% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast6.46%
EPS Growth Forecast-14.32%